NCT04035733View on ClinicalTrials.gov

rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

March 12, 2020

Study Completion Date

April 29, 2020

Conditions

Bullous Pemphigoid (BP)

Interventions

DRUG

rVA576

BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.

Trial Locations (2)

Unknown

University of Lubeck, Lübeck

9700 RB

UMCG Groningen, Groningen

Sponsors

Lead Sponsor

AKARI Therapeutics

All Listed Sponsors

lead

AKARI Therapeutics

INDUSTRY